Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
Wiener Klinische Wochenschrift|November 1, 2011
[Consensus diagnosis and therapy of soft tissue sarcoma]Thomas Brodowicz, Gabriele Amann, Andreas Leithner, et al.
BMC Infectious Diseases|May 28, 2026
Real-world evidence from a tertiary academic center: clinical characteristics, microbiology and outcomes of oncology patients with febrile neutropenia presenting to the emergency departmentMarkus Kleinberger, Petar Popov, Anna Pfarrhofer, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2012
First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind studyGeorge D Demetri, Axel Le Cesne, Sant P Chawla, et al.
Anticancer Research|May 25, 2004
Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancerWolfgang J Köstler, Günther G Steger, Afschin Soleiman, et al.
Wiener Klinische Wochenschrift|July 9, 2013
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone diseaseRodica Anghel, Alexander Bachmann, Meral Bekşac, et al.
Oncology|September 6, 2012
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trialsDominik P Modest, Thomas Brodowicz, Sebastian Stintzing, et al.
Anti-Cancer Drugs|January 19, 2005
Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experienceWolfgang J Köstler, Günther G Steger, Michael Krainer, et al.
Cancers|February 10, 2024
Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13)Bernd Kasper, Daniel Pink, Christian Rothermundt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2004
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancerWolfgang J Köstler, Barbara Schwab, Christian F Singer, et al.
Journal of Cancer Research and Clinical Oncology|May 3, 2005
The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 statusWolfgang J Köstler, Thomas Brodowicz, Gernot Hudelist, et al.
Pageof 9